NGLFINE vs PFIZER: Stock Comparison
NGL Fine-Chem Limited vs Pfizer Limited
Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings
Pfizer Limited is the larger company by market capitalisation. NGL Fine-Chem Limited shows faster revenue growth, while Pfizer Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of NGL Fine-Chem Limited and Pfizer Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NGLFINE | PFIZER |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NGLFINE | PFIZER |
|---|---|---|
| Live Price | ₹3,264.8 | ₹4,653.2 |
| Day Change | 0.85% | 1.3% |
| Volume | 5,412 | 19,684 |
| 52-Week High | ₹3,329 | ₹5,873.5 |
| 52-Week Low | ₹1,175.5 | ₹4,360.1 |
| Distance from 52W High | -1.93% | -20.78% |
Valuation
| Metric | NGLFINE | PFIZER |
|---|---|---|
| Market Cap | ₹2,008 Cr | ₹21,242 Cr |
| P/E Ratio | 41.23x | 29.12x |
| P/B Ratio | 6.03x | 5.01x |
| EPS | ₹78.04 | ₹157.72 |
| Book Value | ₹532.95 | ₹918.74 |
| Dividend Yield | 0.05% | 2.83% |
Growth
| Metric | NGLFINE | PFIZER |
|---|---|---|
| Revenue Growth (TTM YoY) | 57.2% | 6.3% |
| EPS Growth (TTM YoY) | 1,539.8% | -39.6% |
| Qtr Sales Growth | 57.1% | — |
| Qtr Profit Growth | 2,398% | — |
Profitability & Leverage
| Metric | NGLFINE | PFIZER |
|---|---|---|
| ROE | 15.7% | 19.8% |
| ROCE | 17% | 27.2% |
| Net Margin | 9.59% | 28.67% |
| Operating Margin | 14.5% | -12.1% |
| Debt to Equity | 0.33x | 0x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | NGLFINE | PFIZER |
|---|---|---|
| Promoter Holding | 72.74% | 63.92% |
| FII Holding | 0.03%▲ 0.03 pp | 1.65%▼ 1.16 pp |
| DII Holding | 0% | 17.8%▲ 0.91 pp |
| Public Holding | 27.24%▼ 0.02 pp | 16.63%▲ 0.26 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NGL Fine-Chem Limited and Pfizer Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.